ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 8ÔÂ28ÈÕ£¬£¬£¬£¬£¬±±¾©¼ªÔ´ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾µÄ¡°ÈËGLP-1ºÍFGF21Ë«Òò×Ӹ߱í´ïÖ¬·¾¸Éϸ°û×¢ÉäÒº¡±»ñÅúÁÙ´²£¬£¬£¬£¬£¬Ë³Ó¦Ö¢Îª2ÐÍÌÇÄò²¡£¡£¡£¡£¡£¨T2DM£©¡£¡£¡£¡£¡£¼ªÔ´ÉúÎïÌåÏÖ£¬£¬£¬£¬£¬ÕâÊǺ£ÄÚÊ״λùÒòÐÞÊμä³äÖʸÉϸ°ûÖÎÁÆ2ÐÍÌÇÄò²¡µÄÁÙ´²ÊÔÑé»ñÅú¡£¡£¡£¡£¡£
2. 8ÔÂ29ÈÕ£¬£¬£¬£¬£¬CDE¹ÙÍø×îй«Ê¾£¬£¬£¬£¬£¬ÖÐÉú¸´Åµ½¡ÉúÎïÖØ×éÈËIL12/15-PDL1B´¿´âðåÕîIÐÍÈÜÁö²¡¶¾×¢ÉäÒº£¨Veroϸ°û£©ÄâÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖ£¬£¬£¬£¬£¬Ë³Ó¦Ö¢Îª£º¾±ê×¼ÖÎÁÆÊ§°ÜµÄÍíÆÚ¸Îϸ°û°©£¨HCC£©¡£¡£¡£¡£¡£
3. 8ÔÂ28ÈÕ£¬£¬£¬£¬£¬º¼ÖÝÒ×ÎÄÈüÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾µÄ¡°ÈËÆê´ø¼ä³äÖʸÉϸ°û×¢ÉäÒº¡±ÐÂÒ©ÁÙ´²ÊÔÑéÉêÇ루IND£©»ñ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú×¼£¬£¬£¬£¬£¬Ë³Ó¦Ö¢ÎªÖÐÖØ¶ÈÔ˶¯ÐÔÑ×Ö¢ÐÔ³¦²¡£¡£¡£¡£¡£¨Inflammatory Bowel Disease, IBD£©¡£¡£¡£¡£¡£
4. 8ÔÂ28ÈÕ£¬£¬£¬£¬£¬ÄϾ©±´Ë¼°ÂÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾Ê׿î»ùÒòÁÆ·¨¡°BN-1001¡±µÄÁ½ÏîÐÂÒ©ÁÙ´²ÊÔÑéÉêÇ루IND£©»ñ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú×¼£¬£¬£¬£¬£¬Ë³Ó¦Ö¢ÎªÖÎÁÆÐÂÉúѪ¹ÜÐÔ£¨ÊªÐÔ£©ÄêËêÏà¹ØÐԻư߱äÐÔ¡£¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬£¬ÉÐÎÞ¹ûÈ»ÐÅÏ¢Åû¶BN-1001µÄ°Ðµã¡£¡£¡£¡£¡£
1. 8ÔÂ29ÈÕ£¬£¬£¬£¬£¬³É¶¼ÏÈÑÜÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾Ðû²¼Íê³É½üÒÚÔªÐÂÒ»ÂÖÈÚ×Ê¡£¡£¡£¡£¡£´ËÂÖͶ×ÊÓÉ»³¸ñ×ÊÔ´ÊÂͶ£¬£¬£¬£¬£¬Öпƴ´ÐÇ¡¢ÉúÎï³Çݼ´´¡¢»ª²©Æ÷е¡¢¾ûÌ촴Ͷ¡¢µÂºñͶ×Ê¡¢²Ü¼ÒÃúµÈÐÂÀϹɶ«¸úͶ¡£¡£¡£¡£¡£´Ë´ÎÈÚ×ʽ«Ö÷ÒªÓÃÓÚÍÆ¶¯ÏÈÑÜÉúÎïµÄСºËËáÐÂÒ©¹ÜÏßÁÙ´²Ï£Íû£¬£¬£¬£¬£¬½øÒ»²½À©³äÁÙ´²Ç°¹ÜÏß¼°È˲ÅÍŶӡ£¡£¡£¡£¡£
1. 8ÔÂ28ÈÕ£¬£¬£¬£¬£¬ÖÐɽ´óѧÕÔε¡¢¹ãÖÝÊи¾Å®¶ùͯҽÁÆÖÐÐÄÀî½ÜÅäºÏͨѶÔÚNature Cancer£¨IF=23.5£©ÔÚÏß½ÒÏþÌâΪ¡°Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬£¬£¬¸ÃÑо¿Åú×¢Á×Ëá-HDAC6ÏàÊèÉ¢Çý¶¯ÈýÒõÐÔÈéÏÙ°©Ò쳣ȾɫÖʽṹ¡£¡£¡£¡£¡£
[1] Lu, B., Qiu, R., Wei, J. et al. Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer. Nat Cancer (2024). https://doi.org/10.1038/s43018-024-00816-y
Ïà¹ØÐÂÎÅ